Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer's Disease In The United States
TOKYO, Dec 21, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that, effective January 1, 2022, Biogen will reduce the wholesale acquisition cost (WAC) of ADUHELM (aducanumab-avwa) 100 mg/mL injection
United States Centers For Medicare Eisai Co Ltd Biogen Support Services Drug Administration Public Relations Department
Source: finanznachrichten.de